Experimental cell therapy takes on stubborn brain autoimmune disorders
NCT ID NCT07021209
First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new cell therapy called GT719 in 30 adults with recurrent or hard-to-treat neurological autoimmune diseases. The goal is to see if it is safe and how long the cells last in the body. Researchers will also look for early signs that it might help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GT719 cells (a type of cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat neurological autoimmune diseases.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people, so safety and effectiveness are not yet proven. There may be side effects or the treatment may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol. * Expected survival period\>12 weeks. * Any previous systemic treatment must have undergone at least 4 weeks or 5 half lives (whichever is shorter) by the time the participant plans to receive the study treatment. Exclusion Criteria: * History of organ transplantation, splenectomy, and allogeneic or autologous stem cell transplantation. * History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy. * Received systemic corticosteroids at a dose of ≥10 mg/day prednisone equivalent within 7 days prior to GT719 infusion, except for inhaled corticosteroids.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neurological autoimmune diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.